These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 15177216)

  • 1. [Conservative treatment of endometrial cancer and atypical hyperplasia].
    Yazbeck C; Dhainaut C; Thoury A; Driguez P; Madelenat P
    Gynecol Obstet Fertil; 2004 May; 32(5):433-41. PubMed ID: 15177216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
    Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report.
    Corrado G; Baiocco E; Carosi M; Vizza E
    Fertil Steril; 2008 Nov; 90(5):2006.e5-8. PubMed ID: 18692828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conservative management of young patients with endometrial highly-differentiated adenocarcinoma.
    Kalogiannidis I; Agorastos T
    J Obstet Gynaecol; 2011; 31(1):13-7. PubMed ID: 21280986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer.
    Zivanovic O; Carter J; Kauff ND; Barakat RR
    Gynecol Oncol; 2009 Dec; 115(3):504-9. PubMed ID: 19758691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex hyperplasia of the endometrium. Predictive value of curettage vs. hysterectomy specimens.
    Lambert B; Muteganya D; Lepage Y; Boivin Y
    J Reprod Med; 1994 Aug; 39(8):639-42. PubMed ID: 7996530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of endometrial cancer in young women.
    Shah MM; Wright JD
    Clin Obstet Gynecol; 2011 Jun; 54(2):219-25. PubMed ID: 21508691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The management of endometrial hyperplasia: an evaluation of current practice.
    Clark TJ; Neelakantan D; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):259-64. PubMed ID: 16246481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Young women with atypical endometrial hyperplasia or endometrial adenocarcinoma stage I: will conservative treatment allow pregnancy? Results of a French multicentric survey].
    Le Digabel JF; Gariel C; Catala L; Dhainaut C; Madelenat P; Descamps P
    Gynecol Obstet Fertil; 2006 Jan; 34(1):27-33. PubMed ID: 16406735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occult myometrial recurrence after progesterone therapy to preserve fertility in a young patient with endometrial cancer.
    Hurst SA; Hartzfeld KM; Del Priore G
    Fertil Steril; 2008 Mar; 89(3):724.e1-3. PubMed ID: 17570366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view.
    Ricciardi E; Maniglio P; Frega A; Marci R; Caserta D; Moscarini M
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1934-7. PubMed ID: 23242719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endometrial cancer and fertility.
    Rackow BW; Arici A
    Curr Opin Obstet Gynecol; 2006 Jun; 18(3):245-52. PubMed ID: 16735822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
    Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
    Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
    Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Atypical endometrial hyperplasia. Prognosis and course].
    Jensen HH; Hussain SF; Pedersen PH; Andreasson B
    Ugeskr Laeger; 2000 Jan; 162(5):666-9. PubMed ID: 10707601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fertility sparing management of endometrial adenocarcinoma and atypical hyperplasia: a literature review].
    Koskas M; Yazbeck C; Walker F; Delorme P; Azria E; Luton D; Madelenat P
    Bull Cancer; 2012 Jan; 99(1):51-60. PubMed ID: 22212645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Modern tendencies in treatment of atypical glandular hyperplasia--our and foreign experience].
    Ivanov S; Kovachev E; Tsonev A; Abbud A
    Akush Ginekol (Sofiia); 2010; 49(2):47-9. PubMed ID: 20734678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
    Rubatt JM; Slomovitz BM; Burke TW; Broaddus RR
    Gynecol Oncol; 2005 Nov; 99(2):472-6. PubMed ID: 16099019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial cancer: current concepts and management.
    Ball HG; Elkadry EA
    Surg Oncol Clin N Am; 1998 Apr; 7(2):271-84. PubMed ID: 9537976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.
    Gadducci A; Spirito N; Baroni E; Tana R; Genazzani AR
    Gynecol Endocrinol; 2009 Oct; 25(10):683-91. PubMed ID: 19562604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.